Company intelligence / Profile preview
Curadel Pharma
- Ownership
- Private
- Employees
- ~25
- Development stage
- Phase 3
Overview
ZW800–1, a first-in-class zwitterionic drug for optical surgical navigation, has entered Phase 3 pivotal trials to highlight the ureter during abdominopelvic surgery. CPI–003 targeted alpha therapy program in preclinical/early development aims to prevent tumor resistance and regrowth in rare/metastatic cancers. The company’s platform demonstrates strong proof-of-concept data in both imaging and therapeutic applications.
- Therapeutic areas
- OncologyOther
- Modalities
- Targeted alpha therapies (TATs)Zwitterionic radiopharmaceuticalsImaging agents for surgical navigation
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Curadel Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Curadel Pharma.